Description: Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type; and ALPHA-0602, a gene therapy program for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Home Page: www.alphacognition.com
301–1228 Hamilton Street
Vancouver,
BC
V6B 6L2
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Michael E. McFadden | CEO & Director |
| Mr. Kenneth Anthony Cawkell B.A., LL.B. | Founder, Special Advisor, Corp. Sec. & Director |
| Dr. Denis G. Kay Ph.D. | Chief Scientific Officer |
| Ms. Lauren D'Angelo M.B.A. | Chief Commercial Officer |
| Mr. Donald A. Kalkofen B.A. | Chief Financial Officer |
| Ms. Colleen Johns | Sr. VP of Product Devel. |
| Dr. Cedric O'Gorman M.B.A., M.D., MBA | Chief Medical Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.903 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |